Weixing Guo
Overview
Explore the profile of Weixing Guo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
688
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma Z, Lin X, Zhang J, Song X, Yan M, Guo L, et al.
Biosci Trends
. 2024 Dec;
18(6):563-575.
PMID: 39631886
This study aimed at analyzing and comparing the clinical efficacy and prognosis of repeat laparoscopic hepatectomy (r-LH) and radiofrequency ablation (RFA) in treating recurrent hepatocellular carcinoma (RHCC). Clinicopathological data of...
2.
Wei X, Li S, Yan H, Chen S, Li R, Zhang W, et al.
Anim Genet
. 2024 Mar;
55(3):362-376.
PMID: 38480515
Qaidam cattle are a typical Chinese native breed inhabiting northwest China. They bear the characteristics of high cold and roughage tolerance, low-oxygen adaptability and good meat quality. To analyze the...
3.
Sun J, Mao F, Liu C, Zhang F, Jiang D, Guo W, et al.
Signal Transduct Target Ther
. 2023 Sep;
8(1):368.
PMID: 37752117
The majority of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage. Currently, there are only a few therapeutic methods available for patients with advanced HCC and extrahepatic metastasis...
4.
Lei Z, Ma W, Si A, Zhang Y, Yang F, Yu Q, et al.
Aliment Pharmacol Ther
. 2023 Jun;
58(6):611-622.
PMID: 37349908
Background: Immune checkpoint inhibitor (ICI) combination therapy offers a new option for treatment of unresectable intrahepatic cholangiocarcinoma (uICC). Aim: To compare the effect of different anti-PD-1 combination therapies as the...
5.
Guo L, Wei X, Feng S, Zhai J, Guo W, Shi J, et al.
Hepatol Int
. 2022 Oct;
16(6):1368-1378.
PMID: 36271176
Introduction: To compare survival outcomes of radiotherapy (RT) prior to transcatheter arterial chemoembolization (TACE) (RT + TACE) with TACE followed with RT (TACE + RT) in patients with hepatocellular carcinoma...
6.
Li M, He X, Guo W, Yu H, Zhang S, Wang N, et al.
Nat Cancer
. 2022 Feb;
1(7):735-747.
PMID: 35122041
Metabolic reprogramming is a core hallmark of cancer but it remains poorly defined in hepatocellular carcinogenesis (HCC). Here we show that hepatic aldolase B (Aldob) suppresses HCC by directly binding...
7.
Zhang L, Yu J, Liu Y, Guo W, Li Y
Evid Based Complement Alternat Med
. 2021 Apr;
2021:8868267.
PMID: 33927779
Objectives: Yishenjiangyafang is a traditional Chinese medicine used to clinically treat hypertension. This study aimed to explore the effect of yishenjiangyafang on plasma metabolomics in senile spontaneously hypertensive rats (SHRs)....
8.
Yang Y, Mao F, Guo L, Shi J, Wu M, Cheng S, et al.
Dig Liver Dis
. 2021 Feb;
53(4):474-485.
PMID: 33563583
Background: Hepatocellular carcinoma (HCC) is the most predominant primary liver cancer. Extracellular vesicles (EV)-mediated microRNA (miRNA) delivery is critical in cancer metastasis. We aimed to identify the mechanism of HCC...
9.
Jiang Y, Tao Y, Zhang X, Wei X, Li M, He X, et al.
Mol Oncol
. 2020 Nov;
15(2):710-724.
PMID: 33155364
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Here, we identified that increased miR-23a expression in HCC tissues was associated with worse survival. More importantly, we found...
10.
Cheng S, Wei X, Shi J, Guo W, Feng S, Zhai J, et al.
Oncologist
. 2020 Mar;
25(6):e998.
PMID: 32141691
No abstract available.